New brain MRI lesion activity was suppressed ( > 99 % ) in the first 24 weeks after ofatumumab administration ( all doses ) , with statistically significant reductions ( p < 0.001 ) favoring ofatumumab found in new T1 gadolinium-enhancing lesions , total enhancing T1 lesions , and new and/or enlarging T2 lesions .